Integration with a RANKL antibody further enhanced the efficacy of ribosome-inactivating proteins (RIP), disrupting tumor–bone interactions, reducing skeletal-related events, and improving therapeutic outcomes. This evidence concerns the gene TNFSF11 and neoplasm.